Published in Lung Cancer on July 01, 2004
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. Br J Cancer (2006) 1.56
Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. J Am Acad Dermatol (2007) 1.27
Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. J Thorac Oncol (2010) 1.12
Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer (2015) 0.86
Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res (2014) 0.85
Identification of the 'NORE' (N-Oct-3 responsive element), a novel structural motif and composite element. Nucleic Acids Res (2005) 0.80
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.80
Diffusion-weighted imaging vs STIR turbo SE imaging: capability for quantitative differentiation of small-cell lung cancer from non-small-cell lung cancer. Br J Radiol (2014) 0.80
Apparent diffusion coefficient values of diffusion-weighted imaging for distinguishing focal pulmonary lesions and characterizing the subtype of lung cancer: a meta-analysis. Eur Radiol (2015) 0.80
Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice. EJNMMI Res (2011) 0.79
Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways. Biomed Res Int (2013) 0.78
Prophylactic cranial irradiation for patients with small-cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer (2014) 0.78
The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer. Korean J Intern Med (2013) 0.78
Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer. Int J Clin Exp Pathol (2014) 0.77
Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases. Cancer Biol Med (2015) 0.77
Lung cancer stem cells and low-intensity laser irradiation: a potential future therapy? Stem Cell Res Ther (2013) 0.76
Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. J Cancer (2016) 0.75
Immunotherapy treatments for small-cell lung cancer: past, present and future. Lung Cancer Manag (2015) 0.75
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer (2016) 0.75
Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort. J Cancer (2016) 0.75
Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer. Oncol Lett (2017) 0.75
Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors. Oncotarget (2016) 0.75
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol (2003) 6.66
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol (2002) 4.50
National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002. J Natl Cancer Inst (2003) 2.99
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol (2002) 2.07
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res (2004) 1.95
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol (2004) 1.83
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys (2004) 1.83
Cardiotoxicity of cancer therapy. J Clin Oncol (2005) 1.80
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol (2011) 1.73
National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr (2004) 1.70
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer (2006) 1.65
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma (2009) 1.65
Hepatotoxicity of chemotherapy. Semin Oncol (2006) 1.63
Small cell lung cancer: have we made any progress over the last 25 years? Oncologist (2007) 1.62
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg (2004) 1.52
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol (2008) 1.50
A cost-effective algorithm for hereditary nonpolyposis colorectal cancer detection. Am J Clin Pathol (2006) 1.40
Creeping phase II-ism and the medical pharmaceutical complex: weapons of mass distraction in the war against lung cancer. J Clin Oncol (2005) 1.39
Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis. J Thorac Oncol (2006) 1.38
Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst (2002) 1.37
Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol (2003) 1.33
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33
A review of first-line treatment for small-cell lung cancer. J Thorac Oncol (2006) 1.32
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res (2012) 1.25
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol (2009) 1.23
Effect of computerisation on the quality and safety of chemotherapy prescription. Qual Saf Health Care (2006) 1.21
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn (2003) 1.20
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res (2012) 1.16
Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.13
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol (2009) 1.10
Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology (2010) 1.09
Skin metastases in non-small cell lung cancer. Am J Med Sci (2012) 1.09
Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J Psychosoc Oncol (2009) 1.05
Breast sarcomas: current and future perspectives. Breast (2011) 1.05
Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer (2008) 0.99
A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer. Acta Oncol (2008) 0.99
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol (2008) 0.97
Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol Ther (2003) 0.96
Epithelioid soft tissue tumors. Semin Oncol (2009) 0.96
Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Cancer Invest (2007) 0.95
Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature. Bull Cancer (2005) 0.93
Radiation-induced liver disease. J Clin Oncol (2008) 0.93
Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages. J Immunol (2007) 0.92
History of small-cell lung cancer. Clin Lung Cancer (2011) 0.92
Outcome of radiation therapy for renal transplant rejection refractory to chemical immunosuppression. Radiother Oncol (2005) 0.91
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol (2010) 0.91
Scar carcinoma of the lung: a historical perspective. Clin Lung Cancer (2011) 0.91
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm (2006) 0.90
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol (2005) 0.89
Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res (2008) 0.89
(18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. Melanoma Res (2012) 0.89
Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother (2007) 0.88
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer (2008) 0.87
Pulmonary toxicity of chemotherapy. Semin Oncol (2006) 0.87
Current standards and progress in understanding and treatment of GIST. Swiss Med Wkly (2009) 0.87
Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol (2002) 0.87
Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer (2006) 0.86
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet (2012) 0.86
Role of trabectedin in the treatment of soft tissue sarcoma. Onco Targets Ther (2009) 0.86
Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Williston Park) (2003) 0.85
Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer. Oncologist (2003) 0.85
Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol (2008) 0.84
Long-term expansion of transplantable human fetal liver hematopoietic stem cells. Blood (2003) 0.84
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol (2002) 0.84
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients. J Immunother (2010) 0.84
Locally advanced esophageal cancer. Curr Treat Options Oncol (2002) 0.84
High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol (2002) 0.83
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res (2003) 0.83
Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma. Int J Cancer (2008) 0.83
Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer (2003) 0.83
Home care--a safe and attractive alternative to inpatient administration of intensive chemotherapies. Support Care Cancer (2011) 0.82
A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol (2007) 0.81
Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor. Int Immunol (2008) 0.81
[Dangerous liaisons: relation between oncologist and general practitioner]. Rev Med Suisse (2005) 0.80
Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 0.80
Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer (2002) 0.80
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur J Immunol (2006) 0.79
Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53. Fam Cancer (2011) 0.78
Long-term ex vivo expansion of human fetal liver primitive haematopoietic progenitor cells in stroma-free cultures. Br J Haematol (2002) 0.78
Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. J Thorac Oncol (2006) 0.78
Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin Breast Cancer (2004) 0.78
Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. Int J Radiat Oncol Biol Phys (2003) 0.78